Printer Friendly

ALPHA-BETA TECHNOLOGY REPORTS THIRD QUARTER FINANCIAL RESULTS

 WORCESTER, Mass., Nov. 17 ~PRNewswire~ -- Alpha-Beta Technology, Inc. (NASDAQ: ABTI) today reported financial results for the third quarter and nine months ended Sept. 30, 1992. In the third quarter, revenues were $98,488, expenses were $1,665,551, and there was a resulting net loss of $1,567,063, or 21 cents per share. For the nine- month period, revenues were $374,818, expenses totaled $4,663,719, and there was a net loss of $4,288,901, or 58 cents per share.
 "The third quarter was particularly eventful for the company," commented Dr. Spiros Jamas, president and CEO of Alpha-Beta. "Betafectin(tm), our receptor-targeted carbohydrate, entered Phase II clinical trials for the prevention and treatment of infections following major surgery and severe burns, and we signed a landmark agreement with the State of Rhode Island to provide financing for construction of a commercial manufacturing facility for Betafectin. In addition, in mid- October we raised a net of $16,482,000 in an initial public offering."
 Dr. Jamas noted that the third quarter and nine-month results reflected clinical development activities for Betafectin, as well as expanded research and development efforts for Cholestran(tm), the company's fiber-based, cholesterol-lowering agent and Fibercel(tm), a fat substitute.
 Alpha-Beta Technology, Inc. is developing patentable carbohydrate- based products for the health care industry through the application of carbohydrate engineering. The company's major products in development include Betafectin for the treatment and prevention of infections related to surgery, burn injuries and chemotherapy; Cholestran for the treatment and prevention of cardiovascular disease; and Fibercel, a fat substitute. Alpha-Beta's headquarters, laboratory and pilot production facilities are located in Worcester, Mass.
 ALPHA-BETA TECHNOLOGY, INC.
 Condensed Statement of Operations
 (unaudited)
 Three Months Ended Nine Months Ended
 Sept. 30 Sept. 30
 1992 1991 1992 1991
 Revenues:
 Product sales $2,985 $10,075 $17,203 $54,755
 Interest income 95,503 31,063 354,102 69,273
 Other income --- --- 3,513 ---
 Total revenue 98,488 41,138 374,818 124,028
 Expenses:
 Research and
 development 1,080,859 1,082,546 2,894,704 1,974,448
 General and
 administrative 568,017 183,169 1,706,914 704,882
 Interest expense 16,675 12,785 62,101 24,704
 Total expenses 1,665,551 1,278,500 4,663,719 2,704,034
 Net loss $(1,567,063)$(1,237,362) $(4,288,901) $(2,580,006)
 Loss per share (21 cents) (18 cents) (58 cents) (40 cents)
 Shares used in
 calculation of
 net loss per
 share 7,515,079 6,919,702 7,429,368 6,387,160
 -0- 11~17~92
 ~CONTACT: Spiros Jamas, Sc.D., president and CEO of Alpha-Beta Technology, 508-798-6900; or Robert Gottlieb, vice president of Feinstein Partners, 617-577-8110~
 (ABTI)


CO: Alpha-Beta Technology, Inc. ST: Massachusetts IN: MTC SU: ERN

CH -- NE003 -- 1672 11~17~92 08:29 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 17, 1992
Words:472
Previous Article:U.S. ALCOHOL TESTING OF AMERICA INC. ANNOUNCES REVENUE AND LOSSES
Next Article:BRITISH AIRWAYS MAINTAINS PROFIT MOMENTUM $199 MILLION NET PROFIT IN SECOND QUARTER,
Topics:


Related Articles
BIOGEN REPORTS FOURTH QUARTER AND 1991 RESULTS
ALPHA-BETA TECHNOLOGY, INC. ANNOUNCES $20 MILLION PRIVATE PLACEMENT
ALPHA-BETA TECHNOLOGY, INC. COMPLETES $20 MILLION PRIVATE PLACEMENT
ALPHA-BETA TECHNOLOGY, INC. REPORTS 1993 THIRD QUARTER RESULTS
BIOGEN REPORTS FIRST QUARTER EARNINGS OF $0.31 PER SHARE
ALPHA-BETA TECHNOLOGY TO BEGIN PHASE III TRIAL FOR BETAFECTIN(R)PGG-Glucan
Alpha 1 Biomedicals, Inc. Calendar Year 1996 Results
Alpha 1 Biomedicals, Inc. Third Quarter Calendar Year 1997 Results
Maxygen Reports Third Quarter 2003 Financial Results.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters